Morgan Stanley’s Oncobiologics, Inc. Series B Warrant ONSIZ Stock Holding History

Morgan Stanley’s Portfolio ONSIZ Stock Details ONSIZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-6,200	Closed	–	–	6903
2018 Q1	$0	Hold	6,200	–	–	﹤0.01%	6823
2017 Q4	$0	Hold	6,200	–	–	﹤0.01%	6787
2017 Q3	$0	Sell	6,200 -2,750	-31%	-$181	﹤0.01%	6703
2017 Q2	$1K	Hold	8,950	–	–	﹤0.01%	6555
2017 Q1	$4K	Hold	8,950	–	–	﹤0.01%	6402
2016 Q4	$7K	Hold	8,950	–	–	﹤0.01%	6238
2016 Q3	$9K	Buy	8,950 +3,120	+54%	+$2.28K	﹤0.01%	6136
2016 Q2	$2K	Buy	+5,830	New	+$3.07K	﹤0.01%	6391

Morgan Stanley's ONSIZ Position: Q2 2018 in Review

Morgan Stanley sold out of Oncobiologics, Inc. Series B Warrant (ONSIZ) in Q2 2018, closing a stake of 6,200 shares.

Morgan Stanley first reported a position in ONSIZ in Q2 2016 and held it in 8 quarters. The position peaked at $9K in Q3 2016. 0 funds tracked by Wall St. Rank hold ONSIZ as of Q2 2018.

Morgan Stanley reported no remaining Oncobiologics, Inc. Series B Warrant position as of Q2 2018 after selling out during the quarter.
Morgan Stanley sold 6,200 Oncobiologics, Inc. Series B Warrant shares in Q2 2018.
Morgan Stanley first reported a position in Oncobiologics, Inc. Series B Warrant in Q2 2016 and held it in 8 quarters.
Morgan Stanley's Oncobiologics, Inc. Series B Warrant position peaked at $9K in Q3 2016.
0 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series B Warrant as of Q2 2018.

Based on Morgan Stanley's 13F filing for Q2 2018, filed 14 Aug 2018.